Genexine, Inc.
095700.KQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$132.12B
Close$
Share Statistics
| Market cap | $132.12 Billion |
|---|---|
| Enterprise Value | $237.93 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-594.1 |
| Beta | 0.39 |
| Outstanding Shares | 45,480,000 |
Return
| Return on Equity | -16.04% |
|---|---|
| Return on Assets | -9.68% |
| Return on Invested Capital | -3.06% |
Valuation & Multiples
| P/E Ratio | -4.12 |
|---|---|
| PEG | -5.23 |
| Price to Sales | 23.85 |
| Price to Book Ratio | 0.59 |
| Enterprise Value to Revenue | 47.88 |
| Enterprise Value to EBIT | -37.81 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.49 |
| Debt to Equity | 0.58 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 18, 2026
EPS Estimate
$157.81
Average shareholder expectationRevenue Estimate
$972.21 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Genexine, Inc.
86 employees
CEO: Jungwon Woo Genexine, Inc. is a South Korean clinical-stage biotechnology firm dedicated to advancing and commercializing immunotherapeutics and extended-duration biologics. The company leverages two key proprietary technologies: the hyFc platform, ...